• Dr Paula Sommer, Head of Research and Partnerships, Cystic Fibrosis Trust.
  • £500,000 grant to support precision antibiotics for cystic fibrosis
    Dr James Clark, CEO and Co-founder, Glox Therapeutics.
  • Dr Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge, LifeArc.
  • Dr Beverley Isherwood, Strategy Leader, Infectious Diseases, Medicines Discovery Catapult.
  • Dr Paula Sommer, Head of Research and Partnerships, Cystic Fibrosis Trust.
  • £500,000 grant to support precision antibiotics for cystic fibrosis
    Dr James Clark, CEO and Co-founder, Glox Therapeutics.

Company news

£500,000 grant to support precision antibiotics for cystic fibrosis

Glox Therapeutics has been awarded up to £500,000 from the £3 million Collaborative Discovery Programme (CDP), funded by LifeArc through the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The grant will support the development of precision antibiotics to combat antimicrobial-resistant lung infections in cystic fibrosis (CF) patients.

CF, affecting over 162,000 people worldwide, leads to chronic lung infections due to pathogens like Pseudomonas aeruginosa. Over time, these infections can develop resistance to conventional antibiotics, creating a pressing need for effective new treatments.

Glox’s novel bacteriocin-based platform offers precision antibiotics that target resistant bacteria without harming the human microbiome, providing a potential solution to CF-associated infections.

The CDP, led by Medicines Discovery Catapult, LifeArc, and Cystic Fibrosis Trust, promotes collaboration across industry, academia, and healthcare to drive CF antimicrobial research forward. The funding will allow Glox to use this cross-sector expertise to accelerate its drug development.

Dr James Clark, CEO of Glox Therapeutics, said: "This funding and collaboration are critical to advancing our unique antibiotics to tackle AMR in CF, addressing an urgent unmet need."

Dr Catherine Kettleborough, LifeArc, added: "Collaboration is key in overcoming AMR challenges, and we’re excited to support Glox in this important work."

Dr Beverley Isherwood, Medicines Discovery Catapult, and Dr Paula Sommer, Cystic Fibrosis Trust, emphasised the importance of this initiative in developing new treatments to combat the damaging effects of CF lung infections.

More information online


Digital Edition

Lab Asia 32.1 Feb 2025

February 2025

Chromatography Articles - Comparing volumetric and thermal flowmeters for assessing and validating liquid chromatography performance Mass Spectrometry & Spectroscopy Articles - The importa...

View all digital editions

Events

PITTCON 2025

Mar 01 2025 Boston, MA, USA

IFPAC 2025

Mar 02 2025 Bethesda, MD, USA

H2 Forum

Mar 04 2025 Berlin, Germany

Bio-Europe Spring

Mar 17 2025 Milan, Italy

NGVS 2025

Mar 18 2025 Beijing, China

View all events

Redirecting you now.
Labmate Awards Nominations - Open
The Labmate Awards for Excellence 2025 seek to recognise innovation, quality and achievement wherever it occurs within the laboratory sector. Launching this year the Labmate Awards for Excellence 2025 will have eleven voting categories chosen to reflect the broad range of noteworthy contributions that have been made across our industry in the past 12 months. Nominate your company Now.